|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Disopyramide#Adult Indications and Dosage]] |
| {{Disopyramide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Norpace and Norpace CR are indicated for the treatment of documented ventricular [[arrhythmias]], such as sustained ventricular [[tachycardia]], that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser [[arrhythmias]] is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.
| |
| | |
| Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening [[arrhythmias]], should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired.
| |
| | |
| Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular [[arrhythmias]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677 | publisher = | date = | accessdate = 3 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Pyridines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Amides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |